000			03884cam a2200457Mi 4500
001			95168
003			ES-MaUEC
005			20230102112650.0
006			m o d
007			cr |||||||||||
008			161223t20172017si a ob 000 0 eng d
020			_a9789811032998 _q(electronic bk.)
020			_a9811032998 _q(electronic bk.)
020			_z9789811032974
020			_z9811032971
035			_a(OCoLC)967861663 _z(OCoLC)965904239 _z(OCoLC)966195430 _z(OCoLC)974649782 _z(OCoLC)1005810014 _z(OCoLC)1012054001
040			_aIDEBK _cIDEBK _dYDX _dGW5XE _dN$T _dEBLCP _dN$T _dAZU _dUAB _dOCLCF _dCOO _dUPM _dIOG _dESU _dJBG _dIAD _dICW _dICN _dOTZ _dOCLCQ _dIDEBK _dVT2 _dIDB _dU3W _dMERUC _dES-MaUEC _bspa
050		4	_aRC270.8 _bF464 2017 EB
100	1		_aFeng, Tao, _eautor
245	1	0	_aNanomaterial-based drug delivery carriers for cancer therapy _cTao Feng, Yanli Zhao.
264		1	_aAbingdon, Oxon ; _aNew York _bRoutledge Taylor and Francis Group _c2017
264		1	_aSingapore _bSpringer _c2017
264		4	_c2017
300			_a1 recurso en línea (62 páginas) _bilustraciones (algunas a color)
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_atext file _bPDF _2rda
490	0		_aSpringerBriefs in Applied Sciences and Technology : Nanotheranostics _x2191-5318
500			_aSpringerLink _bSpringer Engineering eBooks 2017 English+International
504			_aIncluye referencias bibliográficas
505	0		_aAcknowledgements; Contents; About the Authors; 1 Current Status and Characteristics of Cancer; 1.1 Abnormal Metabolism; 1.2 Abnormal Vasculature; 1.3 Resistance to Anti-proliferative Growth Factors (GFs); 1.4 Unlimited Replicative Potential; 1.5 Immune System Activation and Inflammation; 1.6 Interstitial Pressure; References; 2 Clinical Anticancer Drugs for Cancer Treatment; 2.1 Antimetabolites; 2.2 Antimitotic Agents; 2.3 Alkylating Agents; 2.4 Antitumor Antibiotics; 2.5 Tyrosine Kinase Inhibitors (TKI); 2.6 Cyclin Dependent Kinase (CDK) Inhibitors.
505	8		_a2.7 Poly(ADP-Ribose) Polymerase (PARP) Inhibitors2.8 Histone Deacetyltransferase Inhibitors (HDACi); 2.9 Mitogen-Activated Protein Kinase (MAPK) Kinase (MEK) Inhibitors; 2.10 Serine/Threonine-Protein Kinase B-Raf Inhibitors; 2.11 Mammalian Target of Rapamycin (MTOR) Inhibitors; 2.12 Phosphoinositide 3-Kinase (PI3K) Inhibitors; 2.13 Ribonucleotide Reductase (RNR) Inhibitors; 2.14 DNA Methyltransferase Inhibitors; 2.15 Retinoids; 2.16 Monoclonal Antibodies (MAbs); 2.17 Combination Therapy; References; 3 Nanomaterial-Based Drug Delivery Carriers for Cancer Therapy; 3.1 Introduction.
505	8		_a3.2 Organic Nanomaterials3.2.1 FDA-Approved Liposomes; 3.2.2 Polymer-Based Nanoparticles; 3.2.3 Supramolecular Nanosystems; 3.2.4 Others; 3.3 Inorganic Nanomaterials; 3.3.1 Quantum Dots; 3.3.2 Gold Nanomaterials; 3.3.2.1 Gold Nanoparticles; 3.3.2.2 Gold Nanorods; 3.3.3 Mesoporous Silica Nanoparticles; 3.3.4 Carbon Nanomaterials; 3.3.4.1 Carbon Nanotubes; 3.3.4.2 Graphene; 3.3.4.3 Carbon Dots; 3.3.5 Upconversion Nanoparticles; 3.3.6 Two-Dimensional Nanomaterials; 3.3.7 Others; 3.4 Organic-Inorganic Hybrid Nanomaterials; References; Conclusions.
520	3		_aThis brief summarizes different types of organic and inorganic nanomaterials for drug delivery in cancer therapy. It highlights that precisely designed nanomaterials will be the next-generation therapeutic agents for cancer treatment.
650		7	_aAntineoplásicos _2embne _0(OCoLC)fst00810595 _0 _9405304
700	1		_aZhao, Yanli, _eautor
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-981-10-3299-8 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
988			_aEBOOK, asignarmaterias, EBSPRINGER_2017B
998			_b02/2018 _dz _e- _zSI
999			_c95168 _d95168 _x1